<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2500-5006</journal-id>
<journal-title><![CDATA[Revista Colombiana de Nefrología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. colom. nefrol.]]></abbrev-journal-title>
<issn>2500-5006</issn>
<publisher>
<publisher-name><![CDATA[Asociación Colombiana de Nefrología e Hipertensión Arterial]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2500-50062019000200122</article-id>
<article-id pub-id-type="doi">10.22265/acnef.6.2.370</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Caracterización clínica de pacientes con nefropatía lúpica en Santander, la importancia de la biopsia renal]]></article-title>
<article-title xml:lang="en"><![CDATA[Clinical and epidemiological characterization of patients with lupus nephropathy in Santander, Colombia: the importance of the renal biopsy]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Torres-Bustamante]]></surname>
<given-names><![CDATA[Mariana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Palomino-Suárez]]></surname>
<given-names><![CDATA[Daniela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Celis]]></surname>
<given-names><![CDATA[Ana M]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Nuñez]]></surname>
<given-names><![CDATA[Sergio F]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández-Sierra]]></surname>
<given-names><![CDATA[Astrid]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Fresenius Medical Care  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Colombia</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Autónoma de Bucaramanga  ]]></institution>
<addr-line><![CDATA[ Santander]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2019</year>
</pub-date>
<volume>6</volume>
<numero>2</numero>
<fpage>122</fpage>
<lpage>129</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S2500-50062019000200122&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S2500-50062019000200122&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S2500-50062019000200122&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: el lupus eritematoso sistémico (LES) presenta diferentes manifestaciones clínicas, un de estas es la nefropatia lúpica (NL), que se asocia con progresión a enfermedad renal crónica (ERC) avanzada y mortalidad.  Objetivo: determinación de las características clínicas y epidemiológicas de la NL en Santander.  Métodos: estudio observacional descriptivo tipo serie de casos en pacientes con NL evaluados por primera vez, entre enero de 2017 a enero 2018, en consulta de nefroprevención. Según criterios de inclusión y exclusión se definieron variables cualitativas y cuantitativas. Se revisaron historias clínicas y el análisis de datos se realizó por medio de SPSS®.  Resultados: se estudiaron 14 pacientes (85 % mujeres), la edad promedio de diagnóstico de NL fue de 36 años, con ERC 1 y 2 (72 %) y con proteinuria A3 (85 %). Se obtuvo biopsia renal en 64 %, con resultado concluyente en el 50 %, la clase histopatológica IV de NL fue la más común. La terapia de mantenimiento más frecuente fue corticoide en monoterapia (36 %), seguido de la combinación de corticoide y micofenolato (29 %).  Conclusión: la NL predomina en mujeres jóvenes, en estadios tempranos de ERC con altos grados de proteinuria, por lo que se debe realizar una evaluación minuciosa en búsqueda de NL a todos los pacientes con LES, mediante programas de detección y seguimiento nefrológico temprano. El grado histopatológico IV fue el más frecuente, similar a lo reportado en Latinoamérica. Existen dificultades administrativas y técnicas en la toma de biopsias renales, se debe hacer énfasis en la necesidad de su realización, por su primordial importancia para definir el tratamiento.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction: Systemic Lupus Erythematosus (SLE) has different clinical manifestations, being very relevant lupus nephropathy (NL) because is associated with progression to advanced chronic kidney disease (CKD) and mortality.  Objective: Determination of the clinical and epidemiological characteristics of the NL in Santander.  Methods: A descriptive observational study of a series of cases in patients with NL diagnosis, evaluated between January 2017 and 2018 for the first time in a nephroprotection consultation. Qualitative and quantitative variables are defined according to the inclusion and exclusion criteria. Electronic medical records were reviewed, and data analysis was performed through SPSS®.  Results: 14 patients (85% women) were studied. The average age of diagnosis of NL was 36 years, mostly with stages of CKD 1 and 2 (72%) with proteinuria A3 (85%).Biopsy renal was performed in the 64%, a conclusive result in the 50%, being the histopathological grade IV of NL the most common. The most frequent maintenance therapy was corticosteroid alone (35.7%), followed by the combination of corticosteroid and mycophenolate (28.5%).  Conclusion: NL predominates in young women, and presenting in early stages of CKD, with high degrees of proteinuria, so a thorough evaluation should be performed in search of NL in all patients with SLE through early nephrological screening and monitoring programs. The histopathological grade IV found is like that reported in Latin America. There are administrative and technical difficulties in the performance of renal biopsies, emphasis should be placed on the realization of this procedure because it takes a primary role in defining the treatment.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Colombia]]></kwd>
<kwd lng="es"><![CDATA[lupus eritematoso sistémico]]></kwd>
<kwd lng="es"><![CDATA[nefropatía]]></kwd>
<kwd lng="es"><![CDATA[lúpica]]></kwd>
<kwd lng="es"><![CDATA[biopsia]]></kwd>
<kwd lng="es"><![CDATA[proteinuria]]></kwd>
<kwd lng="es"><![CDATA[insuficiencia renal crónica]]></kwd>
<kwd lng="en"><![CDATA[Colombia]]></kwd>
<kwd lng="en"><![CDATA[Lupus Erythematosus Systemic]]></kwd>
<kwd lng="en"><![CDATA[Lupus Nephropathy,Biopsy]]></kwd>
<kwd lng="en"><![CDATA[proteinuria]]></kwd>
<kwd lng="en"><![CDATA[chronic kidney insuficency]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pons-Estel]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Alarcón]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
<name>
<surname><![CDATA[Scofield]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Reinlib]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Cooper]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Understanding the Epidemiology and Progression of Systemic Lupus Erythematosus]]></article-title>
<source><![CDATA[Semin Arthritis Rheum.]]></source>
<year>2010</year>
<volume>39</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1-23</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fernández-ávila]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Rincón-riaño]]></surname>
<given-names><![CDATA[DN]]></given-names>
</name>
<name>
<surname><![CDATA[Cock]]></surname>
<given-names><![CDATA[DR]]></given-names>
</name>
</person-group>
<source><![CDATA[Prevalencia y características demográficas del Lupus Eritematoso Sistémico en Colombia, según información del Sistema Integral de Información de la Protección Social]]></source>
<year>2017</year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hanly]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[O&#8217;Keeffe]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[Su]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Urowitz]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Romero-Diaz]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gordon]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The frequency and outcome of lupus nephritis: results from an international inception cohort study]]></article-title>
<source><![CDATA[Rheumatology]]></source>
<year>2016</year>
<volume>55</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>252-62</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Almaani]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Meara]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rovin]]></surname>
<given-names><![CDATA[BH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Update on Lupus Nephritis]]></article-title>
<source><![CDATA[Clin J Am Soc Nephrol.]]></source>
<year>2017</year>
<volume>12</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>825-35</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pons-Estel]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Catoggio]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cardiel]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Soriano]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
<name>
<surname><![CDATA[Gentiletti]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Villa]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The GLADEL Multinational Latin American Prospective Inception Cohort of 1,214 Patients with Systemic Lupus Erythematosus: Ethnic and Disease Heterogeneity among &#8220;Hispanics.&#8221;]]></article-title>
<source><![CDATA[Medicine (Baltimore)]]></source>
<year>2004</year>
<volume>83</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-17</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pinto Peñaranda]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nefropatía lúpica]]></article-title>
<source><![CDATA[Rev. Colomb. Nefrol.]]></source>
<year>2014</year>
<volume>1</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>104-17</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anaya]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Cañas]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mantilla]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
<name>
<surname><![CDATA[Pineda-Tamayo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Tobón]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Herrera-Diaz]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lupus nephritis in colombians: Contrasts and comparisons with other populations]]></article-title>
<source><![CDATA[Clin Rev Allergy Immunol.]]></source>
<year>2011</year>
<volume>40</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>199-207</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anaya]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Uribe]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
<name>
<surname><![CDATA[Pinto]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
<name>
<surname><![CDATA[Molina]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical and immunological factors associated with lupus nephritis in patients from northwestern Colombia]]></article-title>
<source><![CDATA[Biomedica]]></source>
<year>2003</year>
<volume>23</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>293-300</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arroyo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[García]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Aroca]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Acosta]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Correlación clínica e inmunohistopatológica de la nefropatía lúpica en un centro de referencia del Caribe colombiano durante los años 2012 a 2013]]></article-title>
<source><![CDATA[Rev Colomb Nefrol]]></source>
<year>2014</year>
<volume>1</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>57-64</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aroca]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Modelo de gestión de salud de la nefritis lúpica]]></source>
<year>2017</year>
<page-range>277</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yokoyama]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Okuyama]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinicopathological insights into lupus glomerulonephritis in Japanese and Asians]]></article-title>
<source><![CDATA[Clin Exp Nephrol.]]></source>
<year>2011</year>
<volume>15</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>321-30</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schwartz]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Korbet]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Lewis]]></surname>
<given-names><![CDATA[EJ]]></given-names>
</name>
<name>
<surname><![CDATA[Study]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The prognosis and pathogenesis of severe lupus glomerulonephritis]]></article-title>
<source><![CDATA[Nephrol Dial Transpl.]]></source>
<year>2008</year>
<volume>23</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>1298-306</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruiz-Irastorza]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Espinosa]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Frutos]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Jiménez-Alonso]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Praga]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pallarés]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnóstico y tratamiento de la nefritis lúpica Documento]]></article-title>
<source><![CDATA[Rev Nefrol.]]></source>
<year>2012</year>
<volume>32</volume>
<numero>^s1</numero>
<issue>^s1</issue>
<supplement>1</supplement>
<page-range>1-35</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fanouriakis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kostopoulou]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Alunno]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Aringer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bajema]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Boletis]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2019 Update of the EULAR recommendations for the management of systemic lupus erythematosus]]></article-title>
<source><![CDATA[Ann Rheum Dis.]]></source>
<year>2019</year>
<volume>78</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>736-45</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<collab>Kidney Disease Improving Global Outcomes</collab>
<article-title xml:lang=""><![CDATA[KDIGO Clinical practice guideline for glomerulonephritis]]></article-title>
<source><![CDATA[Kidnet Int Suppl]]></source>
<year>2012</year>
<volume>2</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>1-274</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lightstone]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Doria]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ward]]></surname>
<given-names><![CDATA[FL]]></given-names>
</name>
<name>
<surname><![CDATA[Larosa]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Bargman]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Can we manage lupus nephritis without chronic corticosteroids administration?]]></article-title>
<source><![CDATA[Autoimmun Rev]]></source>
<year>2018</year>
<volume>17</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>4-10</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pons-Estel]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Bonfa]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Soriano]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
<name>
<surname><![CDATA[Cardiel]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Izcovich]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Popoff]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology]]></article-title>
<source><![CDATA[Ann Rheum Dis.]]></source>
<year>2018</year>
<page-range>1-9</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Isenberg]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Appel]]></surname>
<given-names><![CDATA[GB]]></given-names>
</name>
<name>
<surname><![CDATA[Contreras]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Dooley]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Ginzler]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Jayne]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study]]></article-title>
<source><![CDATA[Rheumatology]]></source>
<year>2010</year>
<volume>49</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>128-40</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pons-Estel]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Alarcón]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
<name>
<surname><![CDATA[Hachuel]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Boggio]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Wojdyla]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Pascual-Ramos]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort]]></article-title>
<source><![CDATA[Rheumatology (Oxford)]]></source>
<year>2012</year>
<volume>51</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1293-8</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
